Patient Support

With today's pharmacy landscape shaken by unprecedented and wider disruption to healthcare support and delivery, community and independent entities strive to remain an integral cog in the mix.

With great power comes great responsibility. In this case, tackling these obstacles is vital to making sure that the positives of GLP-1s are not outweighed by the downfalls of improper waste disposal.

A panel dives into the current and future outlook of healthcare policies.

A cohort study aims to connect the dots between incident AWVs among older adults with the first ADRD or MCI diagnosis who receive Medicare fee-for-service benefits.

A deep dive into the future of patient service programs and the value of transparency throughout the process.

In this video interview with Pharma Commerce Editor Nicholas Saraceno, John Stefankiewicz, VP of Analytics, Cencora, details why these pharmacy deserts have become so widespread.

When it comes to navigating the complex clinical and commercial landscape for specialty drugs—including hurdles in access to these critical but costly therapies—today’s specialty pharmacies are bringing more skills and services to the table.

Are these statistical characteristics—along with social determinants of health—associated with denials of preventive care claims?

Why looming benefit changes—and the resulting unintended consequences—are a concern for patients.

The provider’s partnership with AI innovator Odaia offers deeper, broader insights to HCP activity.

A study examines if this PCP-large health system dynamic impacts patient outcomes.

A cross-sectional study investigates changes in Medicare Advantage enrollment among Medicare beneficiaries with end-stage renal disease in the first two years of the Act.

How can industry stakeholders ensure the quality and supply chain security of existing product?

A prediction of how this shift toward patient-centric care may look.

A secret shopper survey study investigates how an FDA approval impacts patient access to a medication used to combat drug opioid overdose.

Partnership adds supply chain efficiencies, while prioritizing patient safety.

In the final part of his Pharma Commerce video interview, Josh Marsh, Vice President and General Manager of Cardinal Health Sonexus Access and Patient Support, defines the qualifying characteristics of a specialty lite product, and summarizes the main points of his Asembia panel.

A lack of access could shut out patients in need of maintenance drugs for complex conditions.

What does the legislation mean for patient access leaders, pharma brand managers, and patient service owners? Industry experts weigh in.

In this part of his Pharma Commerce video interview, Josh Marsh, Vice President and General Manager of Cardinal Health Sonexus Access and Patient Support, discusses the impact technology has in relation to patients sticking to their medication plan.

Why the integration of AI-enabled solutions has the potential to boost patient support and engagement across numerous patient care settings.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Josh Marsh, Vice President and General Manager of Cardinal Health Sonexus Access and Patient Support, outlines the main challenges surrounding medication adherence.

Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.

Will the looming changes address the concerns of the patient assistance community?

Gallagher’s 2024 US Physical & Emotional Wellbeing Report outlines ways to meeting evolving needs in the workforce.

The agreement focuses on augmenting the patient support experience, including from an adherence perspective.

A study explores the cost-effectiveness of combining methotrexate with various drugs as a way to combat failed methotrexate monotherapy.

In an interview with Pharma Commerce editor Nicholas Saraceno, Peter Ax, UpScriptHealth’s founder and CEO, discusses how patients are affected by these supply chain bottlenecks, along with ways to mitigate these complications.

Why these programs require a hybrid approach that combines technology and human connection.

An economic evaluation study assesses these costs by therapeutic class, while identifying trends in pharma R&D intensity over time.